ID   DFCI024
AC   CVCL_A762
SY   DFCI 024; DFCI.024; Dana-Farber Cancer Institute 024
DR   Cosmic; 1165894
DR   DepMap; ACH-001058
DR   GEO; GSM794264
DR   PharmacoDB; DFCI024_289_2019
DR   Wikidata; Q54831032
RX   PubMed=18594010;
RX   PubMed=20679594;
RX   PubMed=26929325;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=31068700;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   HLA typing: A*24:02,33:01:01; B*04:02:01,35:02:01; C*08:02,04:01:01 (PubMed=26929325).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: DepMap; ACH-001058; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=20679594
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 8,13
ST   D5S818: 10,12
ST   D7S820: 9
ST   TH01: 6,9.3
ST   TPOX: 12
ST   vWA: 16,18
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 17
//
RX   PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168;
RA   Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E.,
RA   Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J.,
RA   Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P.,
RA   Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.;
RT   "EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung
RT   cancer.";
RL   Clin. Cancer Res. 14:4275-4283(2008).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=26929325; DOI=10.1073/pnas.1521812113;
RA   Tripathi S.C., Peters H.L., Taguchi A., Katayama H., Wang H.,
RA   Momin A., Jolly M.K., Celiktas M., Rodriguez-Canales J., Liu H.,
RA   Behrens C., Wistuba I.I., Ben-Jacob E., Levine H., Molldrem J.J.,
RA   Hanash S.M., Ostrin E.J.;
RT   "Immunoproteasome deficiency is a feature of non-small cell lung
RT   cancer with a mesenchymal phenotype and is associated with a poor
RT   outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//